Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.61 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209502 | 0.97 | ADAM17 (0.64) | ADAM17MMP13MMP2 | |
| SCHEMBL6209088 | 0.86 | ADAM17 (0.60) | ADAM17MMP13MMP1MMP3ADAM33 | |
| SCHEMBL6209862 | 0.84 | ADAM17 (0.63) | ADAM17MMP13MMP3MMP2 | |
| SCHEMBL7057241 | 0.82 | ADAM17 (0.76) | ADAM17MMP13 | |
| SCHEMBL6210662 | 0.81 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP2 | |
| SCHEMBL6210993 | 0.81 | ADAM17 (0.54) | ADAM17 | |
| SCHEMBL6371065 | 0.81 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP2 | |
| SCHEMBL6365154 | 0.78 | SPHK2 (0.59) | ADAM17MMP1 | |
| SCHEMBL6100731 | 0.78 | ADAM17 (0.67) | ADAM17MMP13MMP3MMP2 | |
| SCHEMBL2681099 | 0.78 | ADAM17 (0.67) | ADAM17MMP13MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | ADAM17 2/4885MMP13 194/4885MMP1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.